Helixgate

Helixgate

Uncategorized

What is your AI drug repurposing strategy missing?

Fragmented data limits even the most advanced oncology AI. Curated knowledge changes that.

Read More

Published

on

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases

The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.

Read More

Published

on

The buyout involves a portfolio of antibody drugs Candid licensed from China-based biotechs and that UCB sees as part of the “next wave” of care for immunological conditions.

Read More

Continue Reading

Uncategorized

Opinion: Are blue zones real? Answering that question is harder than ever

When French geneticist Jean-Francois Deleuze first launched the AGENOMICS study in 2022, he hoped to identify genetic patterns among 1,200 French citizens who’d lived more than 100 years and to compare those to centenarians hailing from one of the world-famous “blue zones.”

Then he started having doubts.

Read the rest…

Read More

Published

on

When French geneticist Jean-Francois Deleuze first launched the AGENOMICS study in 2022, he hoped to identify genetic patterns among 1,200 French citizens who’d lived more than 100 years and to compare those to centenarians hailing from one of the world-famous “blue zones.”

Then he started having doubts.

Read the rest…

Read More

Continue Reading

Uncategorized

FDA Action Alert: Argenx, AstraZeneca/Daiichi Sankyo, Biogen/Eisai and Cingulate

Published

on

The FDA is looking at a slew of label expansions this month, including one that could open up home-based treatments for Alzheimer’s disease.

Continue Reading
Advertisement

Trending